Cardiovascular Safety of Antihyperglycemic Agents in Type 2 Diabetes: What Does Recent Clinical Trial Data Mean for Your Patients?
Annual Meeting Session on Demand
Effective dates for CE credit: 8/6/2015 – 8/6/2017
AADE and Horizon CME will collaborate to produce an educational initiative for diabetes educators on current strategies for the management of patients with type 2 diabetes. This educational program will educate clinicians on cardiovascular safety of antihyperglycemic agents and the barriers to optimal care of patients with type 2 diabetes. The initiative will consist of 1 live, 60-minute symposium session to be held in during AADE15 Annual Meeting and Exhibition in New Orleans, LA from August 5-8, 2015 and 1 enduring webcast to be developed and hosted on www.freecme.com for 12 months.
This recording of a live presentation is a knowledge-based learning activity.
At the end of this presentation, the participant will be able to:
- Discuss the need for cardiovascular safety data with antiphyperglycemic agents in type 2 diabetes
- Compare and contrast recent clinical trial data on CV safety for antihyperglycemic agents from those of the past and assess its clinical implications
- Describe the role of the CDE in the medication management of patients with type 2 diabetes
- Discuss the importance of evidence-based medicine in the management of patients with type 2 diabetes
- PK/PD profile of inhaled insulin
- Safety and efficacy data for recently approved inhaled insulin
- Clinical scenarios for appropriate use of inhaled insulin
- Contraindications of inhaled insulin
This is a knowledge-based activities designed for individual or groups of diabetes educators, including RNs, RDs, Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistants, MDs, and other health care providers interested in staying up to date on current practices of care for their patients with diabetes and other related conditions.
Jennifer Green, MD
Diabetes and Metabolism Specialist, Endocrinologist, Associate Professor of Medicine
Duke University Hospital
Curtis Triplitt, PharmD, CDE
University of Texas Health Science Center at San Antonio
This educational program is being supported by an independent educational grant from Merck.
Continuing Education Credit
This educational program will provide 1.0 contact hours of continuing education credit. To successfully complete the program to earn CE credit, learners must view the recorded session in its entirety, complete any associated assessment activities, and submit an evaluation survey. A continuing education statement of credit will be provided online.
The American Association of Diabetes Educators is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational program will provide 1.0 contact hours of continuing education credit.
AADE is accredited as a provider of continuing nursing education by the California Board of Registered Nursing (CEP # 10977).
|Registered Dietitians |
The American Association of Diabetes Educators, (AM001) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.0 continuing professional education units (CPEUs) for completion of this program. Continuing Professional Education Provider Accreditation does not constitute endorsement by CDR of a provider, program, or materials.
|Registered Pharmacists |
The American Association of Diabetes Educators is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1.0 contact hours (0.1 CEUs) of continuing education credit.
ACPE Universal Program Number: 0069-9999-15-197-H01-P
Effective Dates: 8/6/2015 – 8/6/2017
It is the policy of the American Association of Diabetes Educators to require that anyone who has an opportunity to affect continuing education activities content (e.g. authors, presenters and program planners) with products or services from a commercial interest with which s/he has financial relationships, discloses those financial relationship/s with commercial entities to participants.
Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant disclosures (or lack thereof) among educational activity faculty and planners are as follows:
- Jennifer Green, MD, Duke University Hospital, Durham, NC, was a Consultant for Merck and gave Institutional research grant support for Merck, GlaxoSmithKline, AstraZeneca, and Janssen.
- Curtis Triplitt, PharmD, CDE, University of Texas Health Science Center at San Antonio, San Antonio, TX, has served on a Speakers Bureau for Boehringer Ingelheim and AstraZeneca.
- Nancy Stonis, AADE, Chicago, IL, has no relevant financial disclosures to report.
- Jackie Bellan, AADE, Chicago, IL, has no relevant financial disclosures to report.
- Leah Johnson, AADE, Chicago, IL, has no relevant financial disclosures to report.
The approval of this educational offering by the AADE does not imply endorsement of specific therapies, treatments, or products discussed in the presentations.
Originally presented on: 8/6/2015
Expiration date: 8/6/2017
You will have access to this learning activity for a period of six months after you enroll, or whenever the activity's CE credits expire (whichever comes first).